biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Feb 21, 2017 1:47pm

119 Views

Post# 25872772

RE:2 pending licensing deals.

Oh, and I forgot this Digitel post from just 5 days ago....

NASDAQ Biotech Index up ~10% this year
and BTI is in a world of hurt.

But today? Pump it with old news. LOL.

2 pending licensing deals.
Tailwinds report.
If one or both is a brand name in the industry as Vaccinex hits a cash milestone and BTI moves its own programs into human testing.

Bullboard Posts

Options trading in a volatile macro environment